MENU
+Compare
IBB
ETF ticker: NASDAQ
AS OF
May 16 closing price
Price
$121.16
Change
+$1.92 (+1.61%)
Net Assets
5.25B

IBB stock forecast, quote, news & analysis

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U... Show more

Category: #Health
IBB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Ad is loading...
A.I.Advisor
a Summary for IBB with price predictions
May 16, 2025

IBB's RSI Indicator recovers from oversold territory

The RSI Indicator for IBB moved out of oversold territory on April 11, 2025. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 24 similar instances when the indicator left oversold territory. In of the 24 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for IBB just turned positive on May 16, 2025. Looking at past instances where IBB's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IBB advanced for three days, in of 329 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 233 cases where IBB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on IBB as a result. In of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IBB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Regeneron Pharmaceuticals (NASDAQ:REGN), IQVIA Holdings (NYSE:IQV), Biogen (NASDAQ:BIIB), Illumina (NASDAQ:ILMN), Exelixis (NASDAQ:EXEL), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Intra-Cellular Therapies (NASDAQ:ITCI).

Industry description

The investment seeks to track the investment results of the NYSE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.

Market Cap

The average market capitalization across the iShares Biotechnology ETF ETF is 4.46B. The market cap for tickers in the group ranges from 21.59M to 151.69B. AMGN holds the highest valuation in this group at 151.69B. The lowest valued company is QTTB at 21.59M.

High and low price notable news

The average weekly price growth across all stocks in the iShares Biotechnology ETF ETF was 4%. For the same ETF, the average monthly price growth was 3%, and the average quarterly price growth was -9%. INZY experienced the highest price growth at 243%, while URGN experienced the biggest fall at -30%.

Volume

The average weekly volume growth across all stocks in the iShares Biotechnology ETF ETF was -1%. For the same stocks of the ETF, the average monthly volume growth was 61% and the average quarterly volume growth was 9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 80
Price Growth Rating: 62
SMR Rating: 90
Profit Risk Rating: 89
Seasonality Score: 17 (-100 ... +100)
View a ticker or compare two or three
IBB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
iShares Trust400 Howard StreetSan Francisco
Phone
1-800-474-2737
Web
www.ishares.com